If you purchased or otherwise acquired KemPharm shares and would like more information regarding the investigation, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org.
KemPharm issued a New Drug Application to the U.S. Food and Drug Administration ("FDA") for their Apadaz product, which was to be marketed as an "abuse-deterrent" opioid with less of an addictive effect than competitor products. On May 5, 2016, KemPharm disclosed that the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the FDA had consulted and voted against using an abuse-deterrent label for Apadaz. The FDA attributed the vote to an issue with the study design of Apadaz making it difficult to use in determining the abuse-deterrent effect of the drug.
When this information was revealed to the investing public, the value of KemPharm declined, causing investors severe harm.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.